Beating Tissue Failure in Oncology - Scorecard - MDSpire

Beating Tissue Failure in Oncology

A patented AI platform trained on NYU Langone research is predicting cancer mutations from haematoxylin and eosin alone — closing the gap for the 25 percent of patients who never reach molecular testing

  • By

  • Helen Bristow

  • June 4, 2026

  • 8 min

Share

Clinical Scorecard: Beating Tissue Failure in Oncology

At a Glance

CategoryDetail
Condition
Key MechanismsAI-powered molecular oncology platform for mutation detection from H&E slides.
Target Population
Care Setting

Key Highlights

  • 25% of oncology cases in the US miss molecular characterization due to tissue failure.

Guideline-Based Recommendations

Diagnosis

  • Use AI prescreening to assess probability of actionable mutations.

Management

  • Implement AI-driven platforms to enhance clinical trial efficiency.

Monitoring & Follow-up

  • Track mutation detection rates and turnaround times.

Risks

  • Potential loss of tissue samples before molecular testing.

Patient & Prescribing Data

Cancer patients with limited access to NGS-based testing.

Clinical Best Practices

  • Integrate AI platforms with existing image management systems.

Related Resources & Content

Original Source(s)

Beating Tissue Failure in Oncology

  • by Helen Bristow

  • June 4, 2026

Related Content

Why We Made a Mobile Digital Pathology Lab

Todd R. Minnigh and his team created ScanVan to address a problem with rare cancer diagnosis that had a particularly personal significance

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence

Case Report: Cytokeratin-positive interstitial reticulum cell tumor with HLA loss of heterozygosity